Product image of Metformina + Sitagliptina Generis Phar (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Metformina + Sitagliptina Generis Phar

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Metformina + Sitagliptina Generis Phar (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride, the active ingredient in Metformina + Sitagliptina Generis Phar, is a biguanide presented as an oral tablet for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus, often in combination with sitagliptin, a DPP‑4 inhibitor. The combination targets both hepatic glucose production and incretin pathways to achieve better glycemic management.

GNH India supplies Metformina + Sitagliptina Generis Phar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, including procurement for public and private health systems.

Manufacturer / TM Owner

Generis Farmacêutica, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metformina + Sitagliptina is indicated for type 2 diabetes mellitus, a chronic metabolic disorder requiring glucose‑lowering therapy.

  • Type 2 diabetes mellitus (initial therapy): lowers HbA1c as part of first‑line treatment.
  • Type 2 diabetes mellitus (add‑on therapy): provides additional glucose reduction when metformin alone is insufficient.
  • Type 2 diabetes mellitus (fixed‑dose combination): simplifies regimen and improves patient adherence.

How It Works

  • Metformin decreases hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while sitagliptin inhibits the dipeptidyl peptidase‑4 enzyme, raising endogenous incretin levels (GLP‑1 and GIP) that increase glucose‑dependent insulin secretion and suppress glucagon release, together improving overall glycemic control.

Side Effects

Metformina + Sitagliptina may cause a range of adverse reactions.

Common Side Effects

  • Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
  • Metallic taste in the mouth.
  • Upper respiratory tract infection symptoms.
  • Headache.
  • Mild hypoglycemia when combined with other glucose‑lowering agents.

Serious or Rare Side Effects

  • Lactic acidosis: rare but potentially fatal metabolic disturbance.
  • Pancreatitis: severe abdominal pain with elevated enzymes.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Hepatic dysfunction: elevated liver enzymes.
  • Acute kidney injury: reduced renal clearance leading to drug accumulation.

Precautions & Warnings

Before prescribing Metformina + Sitagliptina, consider the following precautions.

  • Renal function assessment: evaluate eGFR prior to initiation and periodically thereafter.
  • Lactic acidosis risk: avoid in patients with severe renal impairment or conditions predisposing to hypoxia.
  • Pregnancy and lactation: use only if potential benefits justify potential risks.
  • Drug interactions: review concomitant medications that may affect renal function or increase hypoglycemia.
  • Monitoring: regularly check HbA1c, renal function, and liver enzymes.
  • Store at ambient temperature: keep in the original container, protect from moisture.

Avoid Interactions

Metformina + Sitagliptina can interact with several medicines; categorize them by clinical relevance.

Major Interactions (Avoid)

  • Iodinated contrast agents: may precipitate renal dysfunction and increase lactic acidosis risk.
  • Cimetidine: can raise metformin plasma concentrations, heightening toxicity.
  • Excessive alcohol intake: amplifies risk of lactic acidosis.

Moderate Interactions (Monitor Closely)

  • Sulfonylureas or insulin: increased risk of hypoglycemia.
  • Beta‑blockers: may mask hypoglycemia symptoms.
  • Diuretics (loop or thiazide): can affect renal clearance of metformin.

Frequently Asked Questions

Metformina + Sitagliptina is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus. It combines metformin, which reduces hepatic glucose production, with sitagliptin, which enhances insulin secretion through incretin pathways, offering a complementary approach to lower HbA1c levels.

Metformin Hydrochloride lowers blood sugar primarily by inhibiting hepatic gluconeogenesis, thereby decreasing the amount of glucose released into the bloodstream. It also improves peripheral insulin sensitivity, allowing muscle and fat cells to take up glucose more efficiently.

The specific dose of Metformina + Sitagliptina is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the dosage instructions provided by their prescriber and not adjust the dose on their own.

The safety of Metformina + Sitagliptina in pregnancy or while breastfeeding has not been definitively established. It should only be used if the potential benefits outweigh the possible risks, and the decision must be made by a qualified healthcare provider after careful evaluation.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with metformin alone, the addition of sitagliptin provides greater HbA1c reduction by targeting incretin pathways. Unlike sulfonylureas, it carries a lower risk of hypoglycemia, and unlike insulin, it is administered orally, offering a convenient fixed‑dose option for many patients.

Store the product at ambient temperature, below 25 °C, in its original packaging. Keep it away from moisture and direct sunlight to maintain tablet integrity and potency throughout its shelf life.

Metformina + Sitagliptina is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin, and pancreatitis, which can occur with sitagliptin. Patients should seek immediate medical attention if they experience severe abdominal pain, unexplained weakness, or rapid breathing.

Patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), a history of lactic acidosis, or known hypersensitivity to metformin or sitagliptin should avoid this medication. It is also contraindicated in individuals with acute or chronic metabolic acidosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT